Fennec Pharmaceuticals Inc
TSX:FRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
F
|
Fennec Pharmaceuticals Inc
TSX:FRX
|
US |
|
O
|
Omnicom Group Inc
XMUN:OCN
|
US |
Intrinsic Value
The intrinsic value of Fennec Pharmaceuticals Inc (FRX) under the Base Case is 13.51 CAD per share. Compared with the current market price of 14.78 CAD, the stock appears Overvalued by 9% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Fennec Pharmaceuticals Does
Fennec Pharmaceuticals is a small specialty drug company focused on one main problem in cancer care: protecting children from hearing loss caused by the chemotherapy drug cisplatin. Its lead product, PEDMARK, is a prescription treatment used alongside cisplatin for patients with certain solid tumors. The company’s business is built around developing and commercializing this medicine for hospitals, cancer centers, and pediatric oncologists that treat these patients.
- Headquarters
- United States of America US
- Employees
- 35
- IPO date
- Jun 5, 2001
Revenue & Expenses Breakdown
Fennec Pharmaceuticals Inc
Earnings Waterfall
Fennec Pharmaceuticals Inc
The intrinsic value for Fennec Pharmaceuticals Inc (FRX) under the Base Case is 13.51 CAD.
Compared with the current market price of 14.78 CAD, the stock appears Overvalued by 9% .